Cody Quarnberg, OD
Optometrist · Scottsdale, AZNPI 1902977655
Payments from drug & device makers
Across 246 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$865
- AbbVie$575
- Mallinckrodt Hospital Products Inc.$372
- Bausch & Lomb, A Division Of Bausch Health US, LLC$371
- Dompe US, Inc.$349
- Alcon$267
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,96899%
- Education$371%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 41 | $865 |
| AbbVie(2 entities) | 30 | $575 |
| Mallinckrodt Hospital Products Inc. | 14 | $372 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 22 | $371 |
| Dompe US, Inc. | 14 | $349 |
| Alcon | 12 | $267 |
| Aerie Pharmaceuticals, Inc. | 12 | $245 |
| Bausch & Lomb Americas Inc. | 11 | $202 |
| Tarsus Pharmaceuticals, Inc. | 6 | $185 |
| Oyster Point Pharma, Inc. | 9 | $176 |
| Mallinckrodt Enterprises LLC | 9 | $174 |
| Amgen(2 entities) | 9 | $161 |
| Eyevance Pharmaceuticals LLC | 9 | $152 |
| Kala Pharmaceuticals, Inc. | 8 | $152 |
| Novartis | 9 | $149 |
| Shire North American Group Inc | 8 | $146 |
| Thea Pharma Inc. | 6 | $121 |
| Harrow Eye, LLC | 4 | $106 |
| ANI Pharmaceuticals, Inc. | 2 | $46 |
| Glaukos Corporation | 1 | $41 |
| Tearlab Corp | 2 | $24 |
| Celularity Inc. | 1 | $18 |
| Sight Sciences, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Biotissue Holdings Inc. | 1 | $17 |
| Johnson & Johnson Vision Care, Inc. | 1 | $16 |
| Ocular Therapeutix, Inc. | 1 | $14 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $13 |
| Akorn Operating Company LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMIGAN$115
How this compares
$5,005 in reported general payments places this provider in the 90th percentile of 1,134 optometrist providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 151 | $189,124 |
| LumiganBimatoprost | 265 | $152,832 |
| XiidraLifitegrast | 72 | $94,998 |
| Travoprost | 198 | $35,190 |
| VyzultaLatanoprostene Bunod | 60 | $30,632 |
| RocklatanNetarsudil Mesylat/Latanoprost | 43 | $24,439 |
| CombiganBrimonidine Tartrate/Timolol | 37 | $17,699 |
| Cyclosporine | 28 | $12,665 |
| VevyeCyclosporine | 13 | $12,444 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 75 | $11,537 |
| MieboPerfluorohexyloctane/Pf | 15 | $11,401 |
| Loteprednol Etabonate | 54 | $9,339 |
| Latanoprost | 773 | $8,396 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 35 | $8,044 |
| RhopressaNetarsudil Mesylate | 17 | $7,954 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $575 | $359,654453 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $202 | $137,031147 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $245 | $32,39260 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax | $371 | $14,42068 claims |
| Harrow Eye, LLCVevye | $106 | $12,44413 claims |
| AlconSimbrinza | $267 | $8,04435 claims |
| Kala Pharmaceuticals, Inc.Inveltys | $152 | $5,20812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,134 optometrist providers in Arizona.
Other optometrist in Scottsdale
- Marc BloomensteinScottsdale$2.3M
- Stephen CohenScottsdale$32K
- Andrew ZagelbaumScottsdale$25K
- Amanda GoldbergScottsdale$7K
- Daxa LadScottsdale$6K
- Stephanie WooLake Havasu City$540K
- Kevin HelmuthSacaton$281K
- Christina SorensonGlendale$181K
- Jashpal RajasansiGilbert$120K
- Michelle Marie MijaresFort Defiance$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.